Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists

Clinical Pharmacokinetics

Volumn 32, Issue 1, 1997, Pages 1-29

  Csajka, Chantal ^a   Buclin, Thierry ^a   Brunner, Hans R ^a   Biollaz, Jérôme ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; 2 BUTYL 6 (1 METHOXY 1 METHYLETHYL) 3 [4 [2 (1H TETRAZOL 5 YL)PHENYL]BENZYL] 4(3H) QUINAZOLINONE; 2 ETHYL 4 [2' (1H TETRAZOL 5 YL)BIPHENYL 4 YLMETHOXY]QUINOLINE; 2 ETHYL 5,7 DIMETHYL 3 [4 [2 (2H TETRAZOL 5 YL)PHENYL]BENZYL]IMIDAZO[4,5 B]PYRIDINE; 4 PENTAFLUOROETHYL 2 PROPYL 1 [[2' (1H TETRAZOL 5 YL)BIPHENYL 4 YL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; 5 METHYL 7 PROPYL 8 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 1,2,4 TRIAZOLO[1,5 C]PYRIMIDIN 2(3H) ONE; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL; CIMETIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPROSARTAN; FORASARTAN; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN POTASSIUM; LRB 081; PHENOBARBITAL; PLASMA PROTEIN; RENIN; SAPRISARTAN; SODIUM; TAK 536; TASOSARTAN; TELMISARTAN; UNCLASSIFIED DRUG; VALSARTAN; WATER;

ANGIONEUROTIC EDEMA; ARTERY OCCLUSION; BLOOD PRESSURE; CLINICAL TRIAL; COUGHING; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG PROTEIN BINDING; FLUID BALANCE; GLOMERULUS FILTRATION RATE; HEART FUNCTION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY BLOOD FLOW; KIDNEY DISEASE; LIPOPHILICITY; LIVER METABOLISM; META ANALYSIS; ORAL DRUG ADMINISTRATION; PLASMA RENIN ACTIVITY; PRESSOR RESPONSE; PRIORITY JOURNAL; REVIEW; SODIUM BALANCE; TIME; VERTIGO;

EID: 0031017235     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199732010-00001     Document Type: Review

References (112)

1. Laragh JH, Baer L, Brunner HR, et al. Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. Am J Med 1972; 52: 633-52
2. Ferrario CM. Importance of the renin-angiotensin-aldosterone system (RAS) in the physiology and pathology of hypertension: an overview. Drugs 1990; 39 Suppl. 2: 1-8
3. Johnston CI, Burrell LM. Evolution of the blockade of the renin angiotensin system. Hypertension 1995; 9: 375-80
4. Brunner HR, Nussberger J, Waeber B. Inhibitors of the renin-angiotensin system. Arzneimittel Forschung 1993; 43: 274-8
5. Cody RJ. The clinical potential of renin inhibitors and angiotensin antagonists. Drugs 1994; 47: 586-98
6. Burnier M, Biollaz J. Pharmacokinetic optimisation of angiotensin converting enzyme (ACE) inhibitor therapy. Clin Pharmacokinet 1992; 22: 375-84
7. Pals DT, Masucci FD, Sipos F, et al. A specific competitive antagonist of the vascular action of angiotensin II. Circ Res 1971; 29: 664-72
8. 8-angiotensin II for understanding and treatment of high blood-pressure. Lancet 1973; II (837): 1045-8
9. Brunner HR, Laragh JH. Saralasin in human hypertension: the early experience. Kidney Int 1979; 15 Suppl. 9: S36-43
10. Rongen GA, Lenders JW, Smits P, et al. Clinical pharmacokinetics and efficacy of renin inhibitors. Clin Pharmacokinet 1995; 29: 6-14
11. Brunner HR, Nussberger J, Waeber B. Angiotensin II blockade compared with other pharmacological methods of inhibiting the renin-angiotensin system. J Hypertens 1993; 11 Suppl. 3: S532-8
12. Furukawa Y, Kishimoto S, Nishikawa K. Hypotensive imidatide derivatives. US patent 4,340.598.1982
13. Bauer JH, Reams PG. The angiotensin II type I receptor antagonists: a new class of antihypertensive drugs. Arch intern Med 1995; 155: 1361-8
14. Johnston CI. Angiotensin receptor antagonists: focus on losartan. Lancet 1995; 346: 1403-7
15. Eberhardt RT, Kevak RM, Kang PM, et al. Angiotensin II receptor blockade: an innovative approach to cardiovascular pharmacotherapy. J Clin Pharmacol 1993; 33: 1023-38
16. MacFadyen RJ, Reid JL. Angiotensin receptor antagonists as a treatment for hypertension. J Hypertens 1994; 12: 1333-8
17. Lo M, Goldberg M, McCrea J, et al. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 1995; 58: 641-9
18. Beauchamp H, Chang R, Siegl P, et al. In vivo receptor occupancy of the angiotensin II receptor by nonpeptide antagonists: relationship to in vitro affinities and in vivo pharmacologic potency. J Pharmacol Exp Ther 1995; 272: 612-8
19. Goldberg MR, Lo MW, Chiou R, et al. DuP 532 - initial administration to humans and comparison with losartan of a nonpeptide angiotensin II receptor antagonist. Clin Pharm Ther. In press
20. Stearns RA, Miller RR, Doss GA, et al. The metabolism of DuP 753, a nonpeptide angiotensin II receptor antagonist, by rat, monkey, and human liver slices. Drug Metab Dispos 1992; 20: 281-7
21. Yun C, Lee HS, Lee H, et al. Oxidation of the angiotensin II receptor antagonist losartan (DuP753) in human liver microsomes. Drug Metab Dispos 1995; 23: 285-9
22. Ohtawa M, Takayama F, Saitoh K, et al. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans. Br J Clin Pharmacol 1993; 35: 290-7
23. Munafo A, Christen Y, Nussberger J, et al. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther 1992; 51: 513-21
24. Lo MW, Wissel PS, Bialy GB, et al. Pharmacokinetics of intravenous losartan (MK-954, DuP 753) in man. J Hypertens 1992; 10 Suppl. 4: S133
25. Sica DA, Lo MW, Shaw C, et al. The pharmacokinetics of losartan in renal insufficiency. J Hypertens 1995; 13: S49-52
26. Shum L, Benedek I, Quon C, et al. Pharmacokinetics of DuP 753 (MK954) in healthy male volunteers after single oral ascending doses. Pharm Res 1991; S310
27. Goldberg MR, Lo MW, Bradstreet TE, et al. Effects of cimetidine on pharmacokinetics and pharmacodynamics of losartan, an AT1-selective non-peptide angiotensin II receptor antagonist. Eur J Clin Pharmacol 1995; 49: 115-9
28. McCrea J, Lo M, Tomasko L, et al. Absence of a pharmacokinetic interaction between losartan and hydrochlorothiazide. J Clin Pharmacol 1995; 35: 1200-6
29. Lo MW, Lu H, Farrell DM, et al. Pharmacokinetics of intravenous EXP3174, an active metabolite of losartan in man [abstract]. Pharm Res 1992; 9: S-308
30. Delacrétaz E, Nussberger J, Biollaz J, et al. Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Hypertension 1995; 25: 14-21
31. Ogihara T, Nagano M, Mikami H, et al. Effects of the angiotensin II antagonist, TCV-116, on blood pressure and the renin-angiotensin system in healthy subjects. Clin Ther 1994; 16: 74-86
32. Müller P, Cohen T, De Gasparo M, et al. Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects. Eur J Clin Pharmacol 1994; 47: 231-45
33. Müller P, Flesch G, De Gasparo M, et al. Single- and multiple-dose phase 1 trials with the antagonist valsartan. J Hypertens 1993; 11: S459-60
34. Flesch G, Müller P, Degen P, et al. Absolute oral bioavailability of valsartan in healthy volunteers. Médecine et Hygiène European Journal of Drug Metabolism and Pharmacokinetics, editors. Proceedings of the 6th European Congress of Biopharmacy and Pharmacokinetics, 1996, 163
35. Van den Meiracker AH, Admiraal PJ, Janssen JA, et al. Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension. Hypertension 1995; 25: 22-9
36. Burnier M, Hagman M, Nussberger J, et al. Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects. Hypertension 1995; 25: 602-9
37. Steinhäuslin F, Buclin T, Bouissou P, et al. Angiotensin II (AII) blockade effect of ANA-756 in normal volunteers. Clin Pharmacol Ther 1995; 55: 205
38. Klamerus KJ, Vadiei K, Burghrt P, et al. Ascending, single-dose, safety, tolerance and pharmacokinetics (PK) of 5,8-dihydro-2,4-dimethyl-8-[(2-2′-(1H-tetrazol-5-yl)[1,1′-biphenyl]- 4-y 1)methylyl]pyridol[2,3-d]pyrimidin-7(6H)-one (ANA-756). Clin Pharmacol Ther 195; 57: 203
39. Buclin T, Biollaz J, Küng S, et al. Tolerability, pharmacokinetics and pharmacodynamics of the angiotensin II (Ang II) antagonist TAK-536 in healthy volunteers. Clin Pharmacol Ther 1995; 57: 204
40. Naudin R, Hagmann M, Nussberger J, et al. Oral administration of SC-52458, a specific angiotensin II receptor antagonist, to healthy male volunteers. J Hypertens 1994; 12 Suppl. 3: S93
41. Hagmann M, Delacrétaz E, Nussberger J, et al. Clinical and hormonal assessment of SC-52458, a new orally active angiotensin II receptor antagonist in normontensive volunteers [abstract]. Am J Hypertens 1994; 7: 57A
42. Ganes D, Porter S, Kresevic J, et al. Effect of food on the pharmacokinetics of a capsule formulation of an angiotensin II receptor antagonist. Pharm Res 1994; S435
43. Inglessis N, Nussberger J, Hagmann M, et al. Comparison of the angiotensin II antagonist UP269-6 with the angiotensin converting enzyme inhibitor enalapril in normotensive volunteers challenged with angiotensin I. J Cardiovasc Pharmacol 1995; 25: 986-93
44. Noël B, Del Re G, Capone P, et al. Clinical and hormonal effects of the new angiotensin II receptor antagonist LRB081. J Cardiovasc Pharmacol 1996; 28: 252-8
45. Christ DD. Human plasma protein binding of the angiotensin ii receptor antagonist losartan potassium (Dup 753/MK 954) and its pharmacologically active metabolite EXP3174. J Clin Pharmacol 1995; 35: 515-20
46. Spielberg S, McCrea J, Cribb A, et al. A mutation in CYP2C9 is responsible for decreased metabolism of losartan. Clin Pharmacol Ther 1996; 59: 215
47. McCrea J, Lo MW, Kong T, et al. A rare deficiency of the conversion of losartan to its active metabolite E3174. Clin Pharmacol Ther 1995; 57: 154
48. Wong PC, Price Jr WA, Chiu AT, et al. Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990; 252: 719-25
49. Reidenberg MM. The binding of drugs to plasma proteins and the interpretation of measurements of plasma concentrations of drugs in patients with poor renal function. Am J Med 1977; 62: 466-70
50. McCrea JB, Lo MW, Furtek CI, et al. Ketoconazole does not effect the systemic conversion of losartan to E-3174. Clin Pharmacol Ther 1996; 59: 169
51. Goldberg MR, Lo MW, Deutsch PJ, et al. Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite E-3174. Clin Pharmacol Ther 1996; 59: 268-74
52. Kong AH, Tomasko L, Waldman SA, et al. Losartan does not affect the pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol 1995; 35: 1008-15
53. De Smet M, Schoors D, De Meyer G, et al. Effect of multiple doses of losartan on the pharmacokinetics of single doses of digoxin in healthy volunteers. Br J Clin Pharmacol 1995; 40: 571-5
54. Shibouta Y, Inada Y, Ojima M, et al. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2-2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H- benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (±)-1-(cyclohexylcarbonyloxy) -ethyl-2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)-biphenyl-4-yl]-methyl]-1- benzimidazole-7-carboxylate (TCV-116). J Pharmacol Exp Ther 1993; 266: 114-20
55. Criscione L, Bradley WA, Buhlmayer P, et al. Valsartan: pre-clinical and clinical profile of an antihypertensive angiotensin-II antagonist. Cardiovasc Drug Rev 1995; 13: 230-50
56. Perrier L, Bourrié M, Marti E, et al. In vitro N-glucuronidation of SR 47436 (BMS 186295), a new AT1 nonpeptide angiotensin II receptor antagonist, by rat, monkey and human hepatic microsomal fractions. J Pharmacol Exp Ther 1994; 271: 91-9
57. Bumpus FM, Catt KJ, Chiu AT, et al. Nomenclature for angiotensin receptors: a report of the nomenclature committee of the Council for High Blood Pressure Research. Hypertension 1995; 720-1
58. Timmermans PBMWM, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45: 205-51
59. Sweet CS, Nelson EB. How well have animals studies with losartan predicted responses in humans? J Hypertens 1993; II Suppl. 3: S63-7
60. Olins G, Chen ST, McMahon EG, et al. Elucidation of the insurmountable nalure of an angiotensin receptor antagonist, SC-54629. Mol Pharmacol 1995; 47: 115-20
61. Wong PC, Timmermans PBMWM. Nonpeptide angiotensin II receptor antagonists: insurmountable angiotensin II antagonism of EXP3892 is reversed by the surmountable antagonist DuP 753. J Pharmacol Exp Ther 1991; 258: 49-57
62. Brunner HR, Nussberger J, Waeber B. Dose-response relationships of ACE inhibitors and angiotensin II blockers. Eur Heart J 1994; 15: 123-8
63. Brunner HR, Waeber B, Nussberger J. Does pharmacological profiling of a new drug in normotensive volunteers provide a useful guideline to antihypertensive therapy? Hypertension 1983; 5: 101-7
64. Christen Y, Waeber B, Nussberger J, et al. Noninvasive blood pressure monitoring at the finger for studying short lasting pressor responses in man. J Clin Pharmacol 1990; 30: 711-4
65. Christen Y, Waeber B, Nussberger J, et al. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers: inhibition of pressor response to exogenous angiotensin I and II. Circulation 1991; 83: 1333-42
66. Ogihara T, Nagano M, Higaki J, et al. Persistent inhibition of the pressor and aldosterone response to angiotensin-III by TCV-116 in normotensive subjects. J Cardiovasc Pharmacol 1995; 26: 490-4
67. Harb G, Morgan J, Prasad P, et al. The pressor inhibitory effect of angiotensin-II antagonist (Valsartan, CGP 48933) on angiotensin-II infusions in healthy subjects [abstract]. J Invest Med 1995; 43 Suppl. 2: 239
68. Ribstein J, Sissmann J, Picard A, et al. Effects of the angiotensin II antagonist SR 47436 (BMS 186295) on the pressor response to exogenous angiotensin II and the renin-angiotensin system in sodium replete normal subjects [abstract 2191]. J Hypertens 1994; 12 Suppl. 3: 131
69. Christ DD, Wong PC, Wong YN, et al. The pharmacokinetics and pharmacodynamics of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) in the dog. J Pharmacol Exp Ther 1993; 268: 1199-205
70. Su CAPFS, Van Heiningen PN, Van Lier JJ, et al. Pharmacodynamics of the AII antagonist BIBR0277SE [abstract]. Clin Pharmacol Ther 1995; 55: 205
71. Goldberg MR, Tanaka W, Barchowsky A, et al. Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers. Hypertension 1993; 21: 704-13
72. Burnier M, Rutschmann B, Nussberger J, et al. Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 1992; 22: 339-47
73. Doig J, McFadyen R, Sweet CS, et al. Haemodynamic and renal response to losartan during salt depletion or salt repletion. J Hypertens 1993; 11 Suppl.: S419
74. Byyny RL. Losartan potassium lowers blood pressure measured by ambulatory blood pressure monitoring. J Hypertens 1995; 13 Suppl. 1: S29-33
75. Weber MA, Byyny RL, Pratt JH, et al. Blood pressure effects of the angiotensin II receptor blocker, losartan. Arch Intern Med 1995; 155: 405-11
76. Grossman E, Peleg E, Caroll J, et al. Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension. Am J Hypertens 1994; 7: 1041-4
77. Gansevoort RT, De Zeeuw D, Shahinfar S, et al. Effects of angiotensin II antagonist losartan in hypertensive patients with renal disease. J Hypertens 1994; 12 Suppl. 2: S37-42
78. Shaw W, Keane W, Sica D, et al. Safety and antihypertensive effects of losartan (MK-954; DUP753), a new angiotensin II receptor antagonist, in patients with hypertension and renal disease. Clin Pharmacol Ther 1993; 53: 140
79. Gottlieb SS, Dickstein K, Fleck E, et al. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 1993; 88: 1602-9
80. Gradman AH, Arcuri KE, Goldberg AI, et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995; 25: 1345-50
81. Goldberg MR, Bradstreet TE, McWilliams EJ, et al. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. Hypertension 1995; 25: 37-46
82. Erley C, Bader B, Scheu M, et al. Renal hemodynamics in essential hypertensives treated with losartan. Clin Nephrol 1995; 43 Suppl. 1: S8-11
83. Mallion JM, Bradstreet DC, Makris L, et al. Antihypertensive efficacy and tolerability of once daily losartan potassium compared with captopril in patients with mild to moderate essential hypertension. J Hypertens 1995; 13 Suppl. 1: S35-41
84. Soffer BA, Wright JT, Pratt JH, et al. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995; 26: 112-7
85. Schoenberger JA, et al. Losartan with hydrochlorothiazide in the treatment of hypertension. J Hypertens 1995; 13 Suppl. 1: S43-7
86. Bauer HJ, Reams GP, Wu Z, et al. Effects of losartan on the renin-angiotensin-aldosterone axis in essential hypertension. J Hum Hypertens 1995; 9: 237-43
87. Dahlof B, Keller SE, Makris L, et al. Efficacy and tolerability of losartan potassium and stenolol in patients with mild to moderated essential hypertension. Am J Hypertens 1995; 8: 578-83
88. Kawabata M, Takabatake T, Ohta H, et al. Effects of an angiotensin II receptor antagonist, TCV-116, on renal haemodynamics in essential hypertension. Blood Press 1994; 3: 117-21
89. McIntyre M, MacFadyen RJ, Meredith PA, et al. Comparison of the oral angiotensin II receptor antagonist UP269-6 or enalapril 20 mg on blood pressure and neurohormonal effects in salt-depleted man. J Cardiovasc Pharmacol 1995; 25: 994-1000
90. Nakashima M, Uematsu T, Kosuge K, et al. Pilot study of the uricosuric effect of DUP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 1992; 42: 333-5
91. Schmitt F, Natov S, Martinez F, et al. Renal effects of angiotensin I receptor blockade and converting enzyme inhibition (CE1) in man. J Hypertens 1994; 12 Suppl. 3: S92
92. Burnier M, Pechère-Bertschi A, Nussberger J, et al. Studies of the renal effects of angiotensin II receptor blockade: the confounding factor of acute water loading on the action of vasoactive systems. Am J Kidney Dis 1995; 26: 108-15
93. Boike S, Ilson B, Audet P, et al. The angiotensin II receptor antagonist SK&F 108566 does not increase uric acid (UA) excretion in healthy men. J Am Soc Nephrol 1993; 4: 530
94. Tsunoda K, Abe K, Hagino T, et al. Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension. Am J Hypertens 1993; 6: 28-32
95. Nelson E, Merrill D, Sweet C, et al. Efficacy and safety of oral MK-954 (DuP 753) an angiotensin receptor antagonist, in essential hypertension. J Hypertens 1991; 9 Suppl. 6: S468-9
96. De Zeeuw D, Gansevoort RT, Dullaart RP, et al. Angiotensin II antagonism improves the lipoprotein profile in patients with nephrotic syndrome. J Hypertens 1995; 13 Suppl. 1: S53-8
97. Ilson B, Boike S, Larouche J, et al. The angiotensin II receptor antagonist SB 203220 does not increase uric acid (UA) excretion in healthy men [abstract]. J Am Soc Nephrol 1994; 5: 562
98. Crozier I, Ikram H, Awan N, et al. Losartan in heart failure: hemodynamic effects and tolerability. Circulation 1995; 91: 691-7
99. Shand B, Gilchrist N, Nicholls M, et al. Effect of losartan on haematology and haemorheology in elderly patients with essential hypertension: a pilot study. J Hum Hypertens 1995; 9: 233-5
100. Sweet CS, Bradstreet D, Berman RS, et al. Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension. Am J Hypertens 1994; 7: 1035-40
101. Sissmann J, Bouroudian M, Armagnac C, et al. Angiotensin II blockade in healthy volunteers: tolerability and impact on renin angiotensin system components of single and repeated doses of a new angiotensin II receptor antagonist SR 47436 (BMS 186295). J Hypertens 1994; 12 Suppl. 3: S92
102. Ogihara T, Higashimori K, Masuo K, et al. Pilot study of a new angiotensin II receptor antagonist, TCV-116: effects of a single oral dose on blood pressure in patients with essential hypertension. Clin Ther 1993; 15: 684-91
103. Ogihara T, Arakawa K, Limura O, et al. Open clinical studies on a new angiotensin II receptor antagonist, TCV 116. J Hypertens 1994; 12 Suppl. 1: S35-8
104. Ilson B, Boike S, Audet P, et al. Renal hemodynamic effects of SK&F 108566, a nonpeptide selective angiotensin (AII) receptor AT1 antagonist. Clin Pharmacol Ther 1995; 57: 206
105. Ramsay LE, Yeo WW. Double-blind comparison of losartan, lisinopril and hydrochlorothiazide in hypertensive patients with a previous angiotensin converting enzyme inhibitor-associated cough. J Hypertens 1995; 13 Suppl. 1: S73-6
106. Acker CG, Greenberg A. Angioedema induced by the angiotensin II blocker losartan. N Engl J Med 1995; 333: 1572
107. Golberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995; 75: 792-5
108. Perlman S, Schambye T, Riveros RA, et al. Non-peptide angiotensin agonists. J Biol Chem 1995; 270: 1493-6
109. Davies RO, Gomez HJ, Irvin JD, et al. An overview of the clinical pharmacology of enalapril. Br J Clin Pharmacol 1984; 18 Suppl. 2: 215S-29S
110. Nelson EB, Chrysant SG, Gradman AH, et al. Dose-response study of lisinopril efficacy in hypertension [abstract]. Br J Clin Pharmacol 1985; 25: 470
111. MacFadyen RJ, Meredith PA, Elliott HL. Enalapril clinical pharmacokinetics and pharmacokinetic-pharmacodynamic relationships. Clin Pharmacokinet 1993; 25: 274-82
112. Peck CC, Barr WH, Benet LZ, et al. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Pharm Res 1992; 9: 826-33